India Bans 16 Fixed Dose Combinations: Full List, the Science Behind Each Ban & What Pharma Sourcing Teams Must Do Now
⚠ Immediate effect, no transition window: On June 20, 2026, India's Ministry of Health and Family Welfare prohibited the manufacture, sale and distribution of 16 Fixed Dose Combinations (FDCs) under Section 26A of the Drugs and Cosmetics Act, 1940. The gazette notifications were issued June 11, 2026, and enforcement is immediate — State Drug Controllers have already been directed to act.
In brief: Acting on a Supreme Court directive, the Drugs Technical Advisory Board's (DTAB) Expert Committee reviewed a batch of Fixed Dose Combinations for therapeutic justification and safety, a process that began in 2021 and concluded with a Sub-Committee report in December 2024. The government has now prohibited 16 of these combinations — spanning antibiotic, analgesic/antispasmodic, and dermatological categories — citing lack of scientific justification or unfavourable risk-benefit profiles. For manufacturers, distributors, formulators and their suppliers, this is a compliance deadline that has already passed, not one that is approaching.
1. What Happened: The Ban in Plain Terms
On June 20, 2026, the Press Information Bureau announced that India's Ministry of Health and Family Welfare had prohibited the manufacture for sale, sale, and distribution of 16 Fixed Dose Combinations (FDCs) for human use, effective immediately. The action was taken under Section 26A of the Drugs and Cosmetics Act, 1940, which gives the central government authority to prohibit any drug it considers to pose a risk to human beings when safer alternatives exist, or where the drug lacks therapeutic justification.
Unlike a phase-out or a labelling change, this is a hard stop. The notification states plainly that manufacture, sale, distribution and supply of the 16 identified FDCs "shall stand prohibited with immediate effect across the country." All State Drug Controllers, regulatory authorities and enforcement agencies have been directed to ensure strict implementation.
2. What Triggered It: The Supreme Court-Directed Review Timeline
This was not a snap regulatory decision. It is the outcome of a review process that ran for more than four years, initiated after the Supreme Court directed a comprehensive review of Fixed Dose Combinations available in the Indian market.
Context for procurement teams: This is not India's first FDC review round. The Ministry has prohibited irrational FDCs in previous cycles following the same scientific-review process, so this action is best read as continuation of an established rational-drug-use enforcement pattern rather than a one-off event.
3. The Full List of 16 Banned FDCs
The prohibited compositions span three therapeutic categories. The full list, as notified, is below.
Antibiotic-Based Combinations
| # | Composition |
|---|---|
| 1 | Amoxicillin + Serratiopeptidase |
| 2 | Amoxicillin + Serratiopeptidase + Lactobacillus Sporogenes |
| 3 | Amoxicillin + Cloxacillin + Lactic Acid Bacillus + Serratiopeptidase |
| 4 | Cefadroxil + Probenecid |
| 5 | Cefuroxime + Serratiopeptidase |
Analgesic & Antispasmodic Formulations
| # | Composition |
|---|---|
| 6 | Acetyl Salicylic Acid + Ethoheptazine |
| 7 | Dicyclomine + Paracetamol + Clidinium Bromide |
| 8 | Dicyclomine + Paracetamol + Clidinium Bromide + Chlordiazepoxide |
| 9 | Gliclazide + Chromium Picolinate |
| 10 | Paracetamol + Lignocaine |
Dermatological Preparations
| # | Composition |
|---|---|
| 11 | Aloe Extract + Allantoin + Alphatocopherol Acetate + D-Panthenol + Vitamin A |
| 12 | Aloe Extract + Vitamin E + Dimethicone + Glycerine |
| 13 | Aloe Vera + Jojoba Oil + Vitamin E |
| 14 | Aloe Vera + Orange Oil |
| 15 | Aloe Vera + Jojoba Oil + Wheat Germ Oil + Tea Tree Oil |
| 16 | Aloe Vera + Vitamin E + Herbal |
Note: This article reflects the 16 compositions as listed in the June 20, 2026 PIB release. For legal and regulatory purposes, always verify against the official e-Gazette notification (accessible via egazette.gov.in) and the original PIB release, as gazette documents are the authoritative source.
4. Why Each Category Failed Scientific Review
The Expert Committee's reasoning was combination-specific, not a blanket judgment against FDCs as a drug format. Three patterns of failure recur across the list.
The regulatory read: None of the 16 combinations were banned for being unsafe in isolation — the individual active ingredients largely remain approved and in use elsewhere. The issue in every case was the specific combination: either the added ingredient lacked evidence of benefit, duplicated an existing mechanism, or contradicted current treatment guidelines when combined.
5. What It Means Downstream for Manufacturers & Sourcing Teams
This action sits within a longer-running rational-drug-use enforcement effort in India, and it has practical consequences that extend beyond the companies that hold marketing approvals for these exact 16 brands.
For formulators and manufacturers, continued production of any of the 16 compositions is now a direct violation of Section 26A, with State Drug Controllers directed to enforce strictly. For distributors and retailers, existing inventory of these compositions needs to be reviewed against State Drug Controller guidance on withdrawal or disposal. For API and intermediate suppliers — including those supplying into India from other APAC markets — this is a signal to check whether any current or pipeline supply agreements are tied to formulations that fall on this list, since continued fulfillment could create reputational and compliance exposure even where the supplier itself sits outside India's direct regulatory perimeter.
Broader pattern to watch: India has prohibited multiple rounds of irrational FDCs over the past several years as part of a consistent regulatory direction. Sourcing and formulation teams working in the Indian pharma market should treat FDC rationality as an ongoing screening criterion for new product development, not a one-time compliance check.
6. Compliance Checklist: 5 Actions to Take This Week
7. How APAC Supply Chain Supports Pharma Compliance & Sourcing
APAC Supply Chain connects global buyers with verified pharmaceutical and specialty chemical suppliers across India, China and Southeast Asia. For pharma manufacturers and formulators navigating regulatory shifts like this one, we help teams identify compliant sourcing pathways, verify supplier documentation, and stay ahead of composition-level regulatory changes across the APAC region.
Reviewing Your Formulation Portfolio Against This List?
Our team can help you cross-check supplier relationships, identify compliant reformulation pathways, and connect with verified API and intermediate suppliers across APAC.
Talk to Our Team Explore APAC Supply Chain8. Frequently Asked Questions
The 16 prohibited FDCs span three categories: antibiotic-based combinations (Amoxicillin + Serratiopeptidase; Amoxicillin + Serratiopeptidase + Lactobacillus Sporogenes; Amoxicillin + Cloxacillin + Lactic Acid Bacillus + Serratiopeptidase; Cefadroxil + Probenecid; Cefuroxime + Serratiopeptidase), analgesic and antispasmodic formulations (Acetyl Salicylic Acid + Ethoheptazine; Dicyclomine + Paracetamol + Clidinium Bromide, with and without Chlordiazepoxide; Gliclazide + Chromium Picolinate; Paracetamol + Lignocaine), and seven dermatological Aloe Vera / Aloe Extract combinations. See the full table in Section 3.
The gazette notifications are dated June 11, 2026, and the Press Information Bureau publicly announced the prohibition on June 20, 2026. Enforcement is immediate, with no stated transition or sell-through window.
A DTAB Expert Committee, acting on Supreme Court direction, found these 16 combinations lacked therapeutic justification or carried risks that outweighed their benefit. The reasoning was combination-specific — not a judgment against the individual active ingredients, but against how they were combined.
Section 26A of the Drugs and Cosmetics Act, 1940, which allows the central government to prohibit any drug in the public interest. This is the same provision used in previous rounds of irrational-FDC prohibition in India.
More than four years. The Expert Committee began its review in 2021, the DTAB Sub-Committee submitted its report on December 28, 2024, and the prohibition was formally notified in June 2026.
Immediately cross-check product and supplier portfolios against the 16-item list, halt any production, sale or distribution of matching compositions, and coordinate with State Drug Controllers on inventory and recall obligations.
9. Conclusion
India's prohibition of 16 Fixed Dose Combinations is not a surprise regulatory shock — it is the conclusion of a Supreme Court-directed, multi-year scientific review process that began in 2021. What makes it urgent for industry is the enforcement mechanism: immediate effect, no transition window, and explicit direction to State Drug Controllers to act.
For manufacturers, distributors, formulators and their upstream suppliers, the practical task is straightforward but time-sensitive: verify your portfolio against the list, engage regulators on any affected inventory, and use the Expert Committee's stated reasoning as a screening standard for future FDC development in the Indian market.
If your organization is reviewing its formulation portfolio or supplier relationships against this list — or needs help identifying compliant sourcing pathways across APAC — we welcome the conversation. Reach out to our team at ibd@apacss.com or explore our full industrial and pharmaceutical sourcing portfolio at www.apacss.com.
